ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Trading Halts

Acadia Pharma (ACAD) Fades Early GainsMarch 30, 2016 11:56 AM Aegis Capital Affirms Acadia Pharma (ACAD) at 'Buy' Following Positive FDA Panel Review; Sees Nuplazid Approval SoonMarch 30, 2016 10:44 AM Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid March 30, 2016 6:49 AM Acadia Pharmaceuticals (ACAD) PT LIfted to $44 at Piper Jaffray Amid Panel Backing for NUPLAZIDMarch 30, 2016 6:26 AM Acadia Pharma (ACAD) Surges 25% as Trading ResumesMarch 29, 2016 5:52 PM Acadia Pharma (ACAD) Resumes Trading at 5:45 PM ETMarch 29, 2016 5:43 PM FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the RisksMarch 29, 2016 5:13 PM Acadia Pharma (ACAD) wins FDA panel backing for Nuplazid - BloombergMarch 29, 2016 3:37 PM Acadia Pharma (ACAD) adequately characterized the safety profile of NUPLAZID - FDA PanelMarch 29, 2016 3:19 PM Acadia Pharma's (ACAD) NUPLAZID Seen Effective in Parkinson's - FDA PanelMarch 29, 2016 2:55 PM Acadia Pharma (ACAD) Said Facing 'Tough' Nuplazid Efficacy Questions from FDA PanelMarch 29, 2016 10:14 AM Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID March 29, 2016 7:05 AM ACADIA Pharmaceuticals Stock Trading Halted TodayMarch 29, 2016 7:05 AM Acadia Pharma (ACAD) trading halted with news pendingMarch 29, 2016 7:00 AM